Loading clinical trials...
Loading clinical trials...
ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect in the treatment of castration resistant prostate cancer (CRPC).
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
UCLA
Los Angeles, California, United States
San Bernardino Urological Associates
San Bernardino, California, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Comprehensive Cancer Centers of Nevada & US Oncology Research
Las Vegas, Nevada, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Greenville Hospital System University Medical Center
Greenville, South Carolina, United States
University of Washington/Seattle Cancer Care Alliance
Seattle, Washington, United States
Start Date
October 1, 2009
Primary Completion Date
August 1, 2011
Completion Date
August 1, 2012
Last Updated
September 4, 2020
49
ACTUAL participants
TOK-001
DRUG
TOK-001
DRUG
TOK-001
DRUG
TOK-001
DRUG
TOK-001
DRUG
TOK-001
DRUG
TOK-001
DRUG
TOK-001
DRUG
Lead Sponsor
LTN PHARMACEUTICALS, INC.
NCT06842498
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05691465